Want to see BNTX full AI Analyst Report?
Top Page
BioNTech SE
(NASDAQ:BNTX)
Select Model
Select Model
Rating:51Neutral
Price Target:
$92.00
▲(2.99% Upside)
Action:Reiterated
Date:08/07/26
BNTX scores in the low-50s primarily because weakening profitability and a revenue reset (despite strong gross margins) weigh heavily on financial performance, while technicals show a mild downtrend with limited momentum. The strong balance sheet and earnings-call pipeline progress/cash strength provide support, but valuation is hindered by current losses and guidance highlights continued near-term commercial headwinds and revenue phasing risk.
Positive Factors
Very strong balance sheet and liquidity
EUR 16.6B of cash and very low leverage provide durable financial flexibility to fund late‑stage oncology trials, manufacturing scale-up, and M&A or partnerships without near‑term funding pressure. This supports multi‑year R&D investment and shields operations from cyclical revenue swings.
Negative Factors
Steep revenue reset from peak COVID sales
Revenue has materially declined from pandemic peaks and remains lumpy; lower COVID vaccine demand reduces baseline topline and increases reliance on pipeline commercialization. Sustained lower product demand pressures margins and requires successful launches to restore prior revenue levels over multiple years.
Read all positive and negative factors
Positive Factors
Negative Factors
Very strong balance sheet and liquidity
EUR 16.6B of cash and very low leverage provide durable financial flexibility to fund late‑stage oncology trials, manufacturing scale-up, and M&A or partnerships without near‑term funding pressure. This supports multi‑year R&D investment and shields operations from cyclical revenue swings.
Read all positive factors
BioNTech SE Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much revenue comes from each business line—vaccine sales and partner arrangements (notably revenues tied to the COVID-19 vaccine and Pfizer collaboration), oncology and other therapeutic programs, licensing and collaboration income, and services. Helps investors see whether growth depends on a single product or partner, how much revenue is recurring versus one‑time, and which segments offer sustainable long‑term upside or face regulatory, competitive, or demand risks.
Shows how much revenue comes from each business line—vaccine sales and partner arrangements (notably revenues tied to the COVID-19 vaccine and Pfizer collaboration), oncology and other therapeutic programs, licensing and collaboration income, and services. Helps investors see whether growth depends on a single product or partner, how much revenue is recurring versus one‑time, and which segments offer sustainable long‑term upside or face regulatory, competitive, or demand risks.
Data provided by:
The Fly
The FlyBioNTech SE (BNTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.30B
Dividend YieldN/A
Average Volume (3M)790.74K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth-1.05%
EPS Growth-395.95%
CountryUS
Employees7,807
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.73
Shares Outstanding251,204,360
10 Day Avg. Volume747,669
30 Day Avg. Volume790,737
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$124.58Price Target Upside39.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-5.51
Revenue Forecast (FY)$1.88B
BioNTech SE Business Overview & Revenue Model
Company Description
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which...
How the Company Makes Money
BioNTech makes money primarily by commercializing products and by partnering its technology and drug candidates with larger pharmaceutical companies. Its largest historical revenue and profit driver has been its COVID-19 vaccine collaboration with...
BioNTech SE Earnings Call Summary
Earnings Call Date:Aug 04, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 03, 2026
Earnings Call Sentiment Neutral
The call balances meaningful near‑term financial headwinds (sharp Q2 revenue decline, guidance reduction, increased SG&A and some timeline pushes) against substantial clinical and strategic progress: multiple encouraging Phase II signals (pumitamig, gotistobart), initiation of a Phase III for LCD, continued advancement of mRNA oncology programs, a strong cash position (EUR 16.6B) and active capital return. The pipeline momentum and capital strength mitigate short‑term revenue weakness, but the quarter highlights both execution progress and clear near‑term commercial challenges.Positive Updates
Promising pumitamig Phase II Global Data
Pumitamig (PD-L1/VEGF bispecific) showed robust activity in a global Phase II cohort (40 evaluable patients): unconfirmed ORR 72.5% and confirmed ORR 62.5%. Notable subgroup efficacy: PD-L1 TPS <1% (≈58% of cohort) confirmed ORR 47.6%; TPS 1–49% 77.8%; TPS ≥50% 100% (6/6). Data consistent across China and global cohorts in multiple tumor types (SCLC, NSCLC, TNBC), supporting ongoing pivotal Phase III programs.
Negative Updates
Steep Revenue Decline in Q2 2026
Revenues for Q2 2026 were EUR 106 million vs EUR 261 million in Q2 2025, a decline of EUR 155 million (−59.4% YoY). First half 2026 revenues totaled EUR 224 million. Management attributed the drop primarily to significantly lower COVID‑19 vaccine demand in key markets.
Read all updates
Q2-2026 Updates
Positive
Negative
Promising pumitamig Phase II Global Data
Pumitamig (PD-L1/VEGF bispecific) showed robust activity in a global Phase II cohort (40 evaluable patients): unconfirmed ORR 72.5% and confirmed ORR 62.5%. Notable subgroup efficacy: PD-L1 TPS <1% (≈58% of cohort) confirmed ORR 47.6%; TPS 1–49% 77.8%; TPS ≥50% 100% (6/6). Data consistent across China and global cohorts in multiple tumor types (SCLC, NSCLC, TNBC), supporting ongoing pivotal Phase III programs.
Read all positive updates
Company Guidance
BioNTech revised its full‑year 2026 guidance to revenues of EUR 1.6–1.9 billion, adjusted R&D expenses of EUR 2.0–2.3 billion and adjusted SG&A unchanged at EUR 700–800 million. In Q2 the company reported revenues of EUR 106 million (vs. EUR 261 million a year ago) and H1 revenues of EUR 224 million; Q2 adjusted R&D was EUR 477 million (vs. EUR 509 million) and H1 adjusted R&D was EUR 1,004 million; Q2 adjusted SG&A was EUR 198 million (vs. EUR 137 million) and H1 adjusted SG&A was EUR 349 million. BioNTech ended the quarter with EUR 16.6 billion in cash, cash equivalents and securities (vs. EUR 16.0 billion a year earlier), is executing an up to $1 billion share repurchase program (USD 152 million repurchased so far), expects to recognize a EUR 613 million BMS collaboration payment largely in Q3, and cited a roughly EUR 400 million midpoint guidance reduction driven ~80% by softer COVID vaccine demand (with the remainder from milestone timing and other event‑driven items); near‑term results also reflect impairments and restructuring costs related to manufacturing footprint consolidation.BioNTech SE Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
82
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.64B | 2.76B | 2.75B | 3.82B | 17.31B | 18.98B |
| Gross Profit | 1.87B | 2.14B | 2.21B | 3.22B | 14.32B | 16.07B |
| EBITDA | -941.06M | -628.00M | -367.10M | 1.38B | 13.10B | 15.00B |
| Net Income | -1.69B | -1.09B | -665.30M | 930.30M | 9.43B | 10.29B |
Balance Sheet | ||||||
| Total Assets | 20.33B | 21.98B | 22.53B | 23.01B | 23.28B | 15.83B |
| Cash, Cash Equivalents and Short-Term Investments | 9.74B | 14.83B | 16.78B | 16.55B | 14.06B | 2.07B |
| Total Debt | 315.97M | 267.29M | 254.20M | 219.10M | 212.20M | 301.50M |
| Total Liabilities | 2.58B | 2.76B | 3.12B | 2.76B | 3.22B | 3.94B |
| Stockholders Equity | 17.75B | 19.22B | 19.41B | 20.25B | 20.06B | 11.89B |
Cash Flow | ||||||
| Free Cash Flow | 518.34M | 269.81M | -244.60M | 4.67B | 13.21B | 735.70M |
| Operating Cash Flow | 736.83M | 438.00M | 207.70M | 5.37B | 13.58B | 889.70M |
| Investing Cash Flow | -1.03B | -2.37B | -2.08B | -6.95B | -35.30M | -566.10M |
| Financing Cash Flow | -112.12M | -50.81M | -45.90M | -778.60M | -1.42B | 94.20M |
BioNTech SE Technical Analysis
Negative
89.33
Price Trends
91.38
Positive
93.08
Negative
97.63
Negative
Market Momentum
0.18
Negative
50.02
Neutral
70.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Negative. The current price of 89.33 is below the 20-day moving average (MA) of 92.01, below the 50-day MA of 91.38, and below the 200-day MA of 97.63, indicating a neutral trend. The MACD of 0.18 indicates Negative momentum. The RSI at 50.02 is Neutral, neither overbought nor oversold. The STOCH value of 70.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNTX.
BioNTech SE Risk Analysis
BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNTech SE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | $24.48B | 14.82 | 29.70% | ― | 26.93% | 80.66% | |
74 Outperform | $21.95B | 16.58 | 19.24% | ― | 2.49% | 9.29% | |
68 Neutral | $18.77B | 24.42 | 14.55% | ― | 21.75% | -36.69% | |
64 Neutral | $26.12B | -95.47 | -6.12% | ― | -67.58% | 45.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $23.30B | -11.87 | -9.16% | ― | -1.05% | -395.95% | |
47 Neutral | $25.42B | -7.98 | -39.20% | ― | -27.62% | -6.22% |
* Healthcare Sector Average
BNTX
BioNTech SE
92.12
-21.40
-18.85%
INCY
Incyte
120.52
33.60
38.66%
UTHR
United Therapeutics
501.27
188.14
60.08%
GMAB
Genmab
31.34
8.03
34.45%
MRNA
Moderna
63.65
35.63
127.16%
ROIV
Roivant Sciences
36.28
24.43
206.16%
BioNTech SE Corporate Events
BioNTech Deepens Investment in Oncology as Q2 Loss Widens and New CEO Named
Aug 4, 2026
On August 4, 2026, BioNTech reported second-quarter 2026 results showing revenues falling to €105.6 million, largely because of lower demand for its COVID-19 vaccines, while year-to-date revenues dropped to €223.7 million from €4...
BioNTech Files Mid‑Year 2026 Interim Results and Development Update
Aug 4, 2026
On August 4, 2026, BioNTech SE reported unaudited financial results and a development update for the three and six months ended June 30, 2026, via a Form 6‑K filing with the U.S. Securities and Exchange Commission. The company disclosed inte...
BioNTech Names Industry Veteran Guido Oelkers as New CEO in Major Leadership Transition
Aug 3, 2026
On August 3, 2026, BioNTech SE announced that its Supervisory Board has appointed Guido Oelkers, Ph.D., as Chief Executive Officer, with his start date set no later than February 1, 2027, succeeding co-founder Prof. Ugur Sahin, M.D. Oelkers, a Ger...
BioNTech and Pfizer Secure EU Approval for XFG-Adapted COVID-19 Vaccine for 2026-2027 Season
Jul 29, 2026
Pfizer and BioNTech announced on July 29, 2026 that the European Commission has granted marketing authorization for their 2026-2027 COVID-19 vaccine formula, adapted to the XFG variant of the JN.1 lineage, for individuals aged six months and older...
BioNTech Launches $1 Billion ADS Share Buyback Program on Nasdaq
Jun 8, 2026
On June 8, 2026, BioNTech disclosed operational details of a previously authorized share repurchase program of up to $1.0 billion in American Depositary Shares, approved by its Supervisory and Management Boards on May 7, 2026. The buyback, aimed a...
BioNTech and Bristol Myers Squibb Report Strong Interim Phase 2 Lung Cancer Data for Bispecific Pumitamig
Jun 1, 2026
On May 30, 2026, BioNTech and Bristol Myers Squibb reported interim Phase 2 results from the global Phase 2/3 ROSETTA Lung-02 trial of pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator, combined with chemotherapy in previously ...
BioNTech Highlights Late-Stage Oncology Pipeline and New Data Ahead of 2026 ASCO Meeting
May 22, 2026
On May 22, 2026, BioNTech announced it will present new clinical data and trial updates from its late-stage oncology pipeline at the 2026 ASCO Annual Meeting in Chicago, running from May 29 to June 2. The centerpiece will be oral presentations on ...
BioNTech Shareholders Back All Proposals and Strengthen Supervisory Board at 2026 AGM
May 15, 2026
On May 15, 2026, BioNTech SE held its 2026 Annual General Meeting as a virtual assembly, with 92% of share capital represented and all management proposals approved by a majority of shareholders. The strong turnout and unanimous backing signal bro...
BioNTech Launches $1 Billion ADS Buyback to Support Long-Term Growth Strategy
May 7, 2026
On May 7, 2026, BioNTech SE announced it had authorized a new share repurchase program for up to $1.0 billion of its American Depositary Shares, with purchases allowed through May 6, 2027 and funded from existing cash resources. The buyback is int...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.